Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Sangiorgio VF, Nam A, Chen Z, Orazi A, Tam W. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leuk Res. 2021;100:106495.

Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, et al. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Res. 2021;81(18):4736-4750.

Restin T, Schmugge M, Cushing MM, Haas T. Comparison between intraoperative bleeding score and ROTEM® measurements to assess coagulopathy during major pediatric surgery. Transfus Apher Sci. 2021;60(5):103191.

Imada EL, Sanchez DF, Dinalankara W, Vidotto T, Ebot EM, Tyekucheva S, et al. Transcriptional landscape of PTEN loss in primary prostate cancer. BMC Cancer. 2021;21(1):856.

Iyengar NM, Zhou XK, Mendieta H, El-Hely O, Giri DD, Winston L, et al. Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. NPJ Breast Cancer. 2021;7(1):18.

Kim D, Alperstein SA, Siddiqui MT. Standardizing a volume benchmark for cerebrospinal fluids for optimal diagnostic accuracy. Diagn Cytopathol. 2021;49(2):258-266.

Perez VA, Husain S, Magro CM, Strom MA, Williams KM, Levin LE. A newly described cutaneous reaction at sites of insulin pump use in a child with Type 1 diabetes. Pediatr Dermatol. 2021;38(1):239-241.

Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplant Cell Ther. 2021;27(8):697.e1-697.e5.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.